BioSpace News Archive

Payer Compass, a leading provider of healthcare reimbursement technology and price transparency solutions, is proud to announce the appointment of two key additions to its leadership team.

Specialty drugs, extended hospital stays and complex treatments are major cost drivers in million-dollar+ claims, according to the Sun Life 2019 High-cost claims and injectable drug trends report.

OncLive®, the nation’s leading multimedia resource focused on providing oncology professionals with the most current and insightful information they need to provide the best patient care, will host its latest State of the Science Summit™ on Non-Small Cell Lung Cancer on Tuesday, June 25, from 5-9 p.m. at the DoubleTree by Hilton in Little Rock, Arkansas.

Dr. Natalie Curcio Lands Three 2019 Aesthetic Everything® Awards including “Top Aesthetic Doctor,” "#1 Top Dermatologist Middle America” and “Top Cosmetic Center.” This year’s 2019 Aesthetic Everything® Awards tapped winners from over 40,000 votes cast.

With the rising trend of CBD products, fraudulent companies are being exposed for using harmful chemicals and dilutors in order to exploit this spike in popularity.

Akrevia Therapeutics, a privately-held biopharmaceutical company focused on developing highly-potent, tumor-targeted immuno-oncology therapeutics, today announced that Joseph Farmer has been appointed as Chief Operating Officer.

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS), the leader in RNA-targeted therapeutics, today announced the appointment of a new member to its board of directors effective immediately – Joan E. Herman, MBA, MS, president and chief executive officer of Herman and Associates, LLC

Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), (“Tetraphase” or “the Company”) today announced a corporate reorganization in order to maximize the commercial opportunity for XERAVA™ (eravacycline), the Company’s novel tetracycline antibacterial indicated for the treatment of complicated intra-abdominal infections (cIAI) in patients 18 years of age and older.

Seres Therapeutics, Inc. (Nasdaq: MCRB) (“Seres”), a leading microbiome therapeutics platform company developing a novel class of biological drugs that are designed to treat disease by restoring the function of a dysbiotic microbiome, today announced that it is commencing an underwritten registered public offering of $60.0 million of shares of its common stock.

Data from SELECT-EARLY and SELECT-COMPARE show a significantly higher proportion of patients treated with upadacitinib monotherapy or in combination with methotrexate (MTX) maintaining clinical remission compared with MTX or adalimumab plus MTX, respectively, at 48 weeks